Compare IPHA & CXE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IPHA | CXE |
|---|---|---|
| Founded | 1999 | 1989 |
| Country | France | United States |
| Employees | 163 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 131.4M | 117.6M |
| IPO Year | N/A | N/A |
| Metric | IPHA | CXE |
|---|---|---|
| Price | $1.46 | $3.79 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $5.75 | N/A |
| AVG Volume (30 Days) | 23.2K | ★ 81.8K |
| Earning Date | 03-26-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.36% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | N/A | N/A |
| Revenue This Year | $180.36 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $54.14 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.18 | $3.40 |
| 52 Week High | $2.63 | $3.88 |
| Indicator | IPHA | CXE |
|---|---|---|
| Relative Strength Index (RSI) | 50.44 | 60.17 |
| Support Level | $1.35 | $3.76 |
| Resistance Level | $1.80 | N/A |
| Average True Range (ATR) | 0.08 | 0.04 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 50.00 | 90.00 |
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
Mfs High Income Municipal Trust is a United States-based diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in tax-exempt bonds and tax-exempt notes. The company's investment portfolio has shares from the industry Healthcare, Airports, and Secondary Schools.